Helga Schmetzer

2.1k total citations
93 papers, 1.4k citations indexed

About

Helga Schmetzer is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, Helga Schmetzer has authored 93 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Immunology, 40 papers in Hematology and 28 papers in Oncology. Recurrent topics in Helga Schmetzer's work include Immunotherapy and Immune Responses (35 papers), Acute Myeloid Leukemia Research (34 papers) and Immune Cell Function and Interaction (28 papers). Helga Schmetzer is often cited by papers focused on Immunotherapy and Immune Responses (35 papers), Acute Myeloid Leukemia Research (34 papers) and Immune Cell Function and Interaction (28 papers). Helga Schmetzer collaborates with scholars based in Germany, United States and Norway. Helga Schmetzer's co-authors include Tanja Kroell, Helmut R. Salih, Christoph Schmid, R. Pelka‐Fleischer, Karin Pfister, Johanna Tischer, Hans‐Jochem Kolb, V. Nuessler, Jean Norden and Thomas Duell and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Helga Schmetzer

90 papers receiving 1.4k citations

Peers

Countries citing papers authored by Helga Schmetzer

Since Specialization

Citations

This map shows the geographic impact of Helga Schmetzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helga Schmetzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helga Schmetzer more than expected).

Fields of papers citing papers by Helga Schmetzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helga Schmetzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helga Schmetzer. The network helps show where Helga Schmetzer may publish in the future.

Co-authorship network of co-authors of Helga Schmetzer

This figure shows the co-authorship network connecting the top 25 collaborators of Helga Schmetzer. A scholar is included among the top collaborators of Helga Schmetzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helga Schmetzer. Helga Schmetzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML 2025 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Peter Bojko, Joerg Uwe Schmohl, Christoph Schmid, (unknown), Helga Schmetzer	0
2	Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients’ Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), Joerg Uwe Schmohl, Marcus Hentrich, Peter Bojko, Doris Kraemer, Andreas Rank, Christoph Schmid, Helga Schmetzer	4
3	Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases 2023 ·Biomolecules ·(unknown), Tobias Boeselt, (unknown), (unknown), (unknown), Christoph Schmid, Andreas Rank, (unknown), Andreas Rembert Koczulla, Helga Schmetzer	3
4	Orofacial clefts lead to increased pro-inflammatory cytokine levels on neonatal oral mucosa 2022 ·Frontiers in Immunology ·(unknown), Elena Percivalle, (unknown), Matthias Weider, (unknown), Inés Willershausen, (unknown), Helga Schmetzer, Manuel Weber, Michael Schneider, Benjamin Frey, Udo S. Gaipl, Matthias W. Beckmann, Lina Gölz	3
5	Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in ‘DC-culture-media’ shifts correlations of released chemokines with antileukemic T-cell reactions 2021 ·Immunobiology ·(unknown), (unknown), (unknown), (unknown), Tanja Kroell, (unknown), (unknown), (unknown), Friedhelm R. Schuster, Arndt Borkhardt, Doris Kraemer, (unknown), H. Kolb, Christoph Schmid, Helga Schmetzer	2
6	Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DCleu) 2020 ·Clinical Immunology ·(unknown), (unknown), Helga Schmetzer	13
7	Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells 2018 ·Cellular Immunology ·(unknown), (unknown), (unknown), (unknown), (unknown), I. Harabacz, (unknown), Tanja Kroell, Axel Karenberg, Hans‐Jochem Kolb, Helga Schmetzer	2
8	Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia 2017 ·Frontiers in Immunology ·Anne M. Dickinson, Jean Norden, Shuang Li, Ilona Hromadníková, Christoph Schmid, Helga Schmetzer, (unknown)	106
9	CD4+ and CD8+T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT 2013 ·Immunobiology ·(unknown), Slavoljub Milosevic, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Friedhelm R. Schuster, Tanja Kroell, Dirk H. Busch, Arndt Borkhardt, Hans‐Jochem Kolb, Johanna Tischer, Raymund Buhmann, Helga Schmetzer	19
10	Combined immunophenotyping and fluorescencein situhybridization with chromosome-specific DNA probes allows quantification and differentiation ofex vivogenerated dendritic cells, leukemia-derived dendritic cells and clonal leukemic cells in patients with acute myeloid leukemia 2012 ·Leukemia & lymphoma ·(unknown), (unknown), (unknown), Tanja Kroell, Andreas Hausmann, Johanna Tischer, Hans‐Jochem Kolb, Horst Zitzelsberger, Helga Schmetzer	6
11	Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. 2010 ·PubMed ·(unknown), (unknown), (unknown), (unknown), Karin Pfister, Helga Schmetzer	19
12	The Quality and Quantity of Leukemia-derived Dendritic Cells From Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Are a Predictive Factor for the Lytic Potential of Dendritic Cells-primed Leukemia-Specific T Cells 2010 ·Journal of Immunotherapy ·(unknown), (unknown), (unknown), (unknown), Tanja Kroell, (unknown), Christoph Schmid, (unknown), Johanna Tischer, Hans-Jochen Kölb, Helga Schmetzer	38
13	Glucocorticoid-Induced Tumor Necrosis Factor Receptor–Related Protein Ligand Subverts Immunosurveillance of Acute Myeloid Leukemia in Humans 2009 ·Cancer Research ·Tina Baessler, Matthias Krusch, Benjamin Joachim Schmiedel, (unknown), Katrin M. Baltz, Alexander Wacker, Helga Schmetzer, Helmut R. Salih	66
14	The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders 2009 ·Leukemia & lymphoma ·(unknown), (unknown), (unknown), (unknown), (unknown), Helmut R. Salih, Hans‐Jochem Kolb, Helga Schmetzer	9
15	Expression of poliovirus receptor‐related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies 2005 ·European Journal Of Haematology ·(unknown), (unknown), (unknown), Tanja Kroell, V. Nuessler, Helga Schmetzer	8
16	Leukemia‐Derived Dendritic Cells can be Generated from Blood or Bone Marrow Cells from Patients with Acute Myeloid Leukaemia: A Methodological Approach under Serum‐Free Culture Conditions 2005 ·Scandinavian Journal of Immunology ·(unknown), Horst Zitzelsberger, Tanja Kroell, R. Pelka‐Fleischer, (unknown), (unknown), (unknown), (unknown), Christoph Schmid, Hans-Jochen Kölb, Helga Schmetzer	24
17	Low l‐selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk 2003 ·European Journal Of Haematology ·(unknown), (unknown), (unknown), R. Pelka‐Fleischer, Karin Pfister, V. Nuessler, Helga Schmetzer	10
18	Soluble CD137 (4-1BB) Ligand Is Released Following Leukocyte Activation and Is Found in Sera of Patients with Hematological Malignancies 2001 ·The Journal of Immunology ·Helmut R. Salih, Helga Schmetzer, Christine Burke, Gary C. Starling, Robert R. Dunn, R. Pelka‐Fleischer, V. Nuessler, Peter A. Kiener	52
19	Detection of Acute Myeloid Leukemic Cells in Complete Remission and in Extramedullary Sites by Clonal Analyses 1996 ·Acta Haematologica ·Helga Schmetzer, W. Wilmanns, H. Gerhartz	9
20	Epstein‐barr virus‐positive recipient type B‐cells survive in a “complete chimera” after allogeneic bone‐marrow transplantation 1988 ·International Journal of Cancer ·H. Gerhartz, J. Mittermüller, A Raghavachar, Helga Schmetzer, (unknown), (unknown), (unknown), Hans Wolf	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact